Advertisement

Topics

Preservative-Free Tafluprost (MK2452) for Open-Angle Glaucoma/Ocular Hypertension

2014-08-27 03:17:30 | BioPortfolio

Summary

This study will compare the safety and efficacy of the preservative-free formulation of 0.0015% tafluprost (MK2452) and preservative-free 0.5% timolol maleate in patients with open-angle glaucoma and ocular hypertension. This study will demonstrate that the preservative-free formulation of 0.0015% tafluprost (MK2452) is non-inferior to preservative-free 0.5% timolol maleate.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Open-Angle Glaucoma

Intervention

Preservative-Free MK2452 (Tafluprost), Comparator: timolol

Location

Call for Information
Inglewood
California
United States
90301

Status

Recruiting

Source

Merck

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:17:30-0400

Clinical Trials [904 Associated Clinical Trials listed on BioPortfolio]

Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing

The ideal dosing for preservative-free tafluprost/timolol fixed combination remains to be elucidated. The present study compared the 24-hour intraocular pressure efficacy obtained with taf...

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost. Both preservative containing and prese...

24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

The study investigated the 24-hour efficacy and ocular surface health with preservative-free tafluprost and a combined preservative-free regimen (tafluprost and dorzolamide/timolol fixed c...

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Tim...

Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)

- Main objective is to compare the ability of Latanoprost 0.005% preservative-added ophthalmic solution versus Tafluprost 0.0015% preservative-free ophthalmic solution, both giv...

PubMed Articles [9871 Associated PubMed Articles listed on BioPortfolio]

0.005% Preservative-Free Latanoprost Induces Dry Eye-Like Ocular Surface Damage via Promotion of Inflammation in Mice.

To investigate the side effects of preservative-free 0.005% latanoprost on the murine ocular surface.

Treatment duration and side effect profile of long-term use of intravitreal preservative-free triamcinolone acetonide in uveitis.

Non-infectious uveitis has been treated historically with corticosteroid therapy in varying doses and routes. Triesence, a preservative-free sterile formulation of triamcinolone acetonide, has been us...

Development of a novel ion-pairing UPLC method with cation-exchange solid-phase extraction for determination of free timolol in human plasma.

A novel UPLC-UV method was developed for analysis of timolol in human plasma using a simple, fast, and cost effective ion-exchange SPE procedure, followed by separation on a C UPLC column with a mobil...

The characteristics of a preservative-free contact lens care solution on lysozyme adsorption and interfacial friction behavior.

The population of soft contact lens wearers is increasing, thus the issues of feeling comfortable and contact lens-induced clinical symptoms are concerned. Both lysozyme deposition and mechanical fric...

Anterior Choroidal Thickness Increased in Primary Open-Angle Glaucoma and Primary Angle-Closure Disease Eyes Evidenced by Ultrasound Biomicroscopy and SS-OCT.

To compare the anterior and posterior choroid thickness (ACT and PCT, respectively) in primary open-angle glaucoma (POAG), primary angle-closure disease (PACD), and healthy control subjects.

Medical and Biotech [MESH] Definitions

Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.

Congenital open-angle glaucoma that results from dysgenesis of the angle structures accompanied by increased intraocular pressure and enlargement of the eye. Treatment is both medical and surgical.

A beta-adrenergic antagonist similar in action to PROPRANOLOL. The levo-isomer is the more active. Timolol has been proposed as an antihypertensive, antiarrhythmic, antiangina, and antiglaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

More From BioPortfolio on "Preservative-Free Tafluprost (MK2452) for Open-Angle Glaucoma/Ocular Hypertension"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...

Adempas (riociguat)
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...


Searches Linking to this Trial